Document
Summary
The policy proposition is focused on rituximab as a treatment in acute TTP and elective therapy to prevent TTP relapse within the criteria set out in this document.
Link
Clinical Panel Report: The treatment in acute thrombotic thrombocytopaenia purpura (TTP) and elective therapy to prevent TTP relapse (all ages)
NHS England is not responsible for content on external websites.
Summary
Clinical panel report.
Document
Summary
Clinical panel report – PDF Version.
Link
NHS England: Equality and Health Inequalities Impact Assessment (EHIA)
NHS England is not responsible for content on external websites.
Summary
Equality and Health Inequalities Impact Assessment (EHIA) – Rituximab for the treatment in acute Thrombotic Thrombocytopaenic Purpura (TTP) and elective therapy to prevent TTP relapse (adults and children aged 2 years and above)
Document
Summary
NHS England: Equality and Health Inequalities Impact Assessment (EHIA) – Rituximab for the treatment in acute Thrombotic Thrombocytopaenic Purpura (TTP) and elective therapy to prevent TTP relapse (adults and children aged 2 years and above)
PDF version.
Link
Rituximab treatment for acute TTP: Clinical Commissioning Policy
NHS England is not responsible for content on external websites.
Summary
Clinical commissioning policy.
Rituximab for the treatment in acute Thrombotic Thrombocytopenic Purpura (TTP) and elective therapy to prevent TTP relapse (adults and children aged 2 years and above) (URN: 2103) [220802P]
Document
Summary
Clinical Commissioning Policy
Rituximab for the treatment in acute Thrombotic Thrombocytopenic Purpura (TTP) and elective therapy to prevent TTP relapse (adults and children aged 2 years and above) (URN: 2103) [220802P]
PDF version.
Link
Rituximab treatment for acute TTP: Engagement Report
NHS England is not responsible for content on external websites.
Summary
This report summarises the feedback NHS England received from engagement during the development of this policy proposition, and how this feedback has been considered.
Document
Summary
This report summarises the feedback NHS England received from engagement during the development of this policy proposition, and how this feedback has been considered.
PDF Version.
Link
Evidence Review: Rituximab for acute immune Thrombotic Thrombocytopaenic Purpura (TTP)
NHS England is not responsible for content on external websites.
Summary
View and download the Rituximab for acute immune Thrombotic Thrombocytopaenic Purpura (TTP) evidence reviews here.